BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/4/2014 11:47:00 AM | Browse: 974 | Download: 848
Publication Name World Journal of Gastroenterology
Manuscript ID 4403
Country/Territory Italy
Received
2013-06-28 18:56
Peer-Review Started
2013-06-29 22:40
To Make the First Decision
2013-07-26 18:29
Return for Revision
2013-09-13 09:50
Revised
Second Decision
2013-12-03 21:01
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-12-04 06:27
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-01-10 15:00
Publish the Manuscript Online
2014-02-19 16:57
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Medicine, Research & Experimental
Manuscript Type Autobiography
Article Title Bortezomib effect on E2F and cyclin family members in human hepatocellular carcinoma cell lines
Manuscript Source Invited Manuscript
All Author List Daniele Baiz, Barbara Dapas, Rossella Farra, Bruna Scaggiante, Gabriele Pozzato, Fabrizio Zanconati, Nicola Fiotti, Lara Consoloni, Sara Chiaretti and Gabriele Grassi
Funding Agency and Grant Number
Funding Agency Grant Number
“Fondazione Cassa di Risparmio of Trieste"
“Fondazione Benefica Kathleen Foreman Casali of Trieste”
Italian Minister of Instruction, University and Research (MIUR), PRIN 2010-11 (in part) 20109PLMH2
Corresponding Author Gabriele Grassi, MD, PhD, Department of Life Sciences, University Hospital of Cattinara, Strada di Fiume 447, 34100 Trieste, Italy. ggrassi@units.it
Key Words Bortezomib; Cyclins; E2F family; Hepatocellular carcinoma; Liver; Microarray; 26S proteasome
Core Tip The 26S proteasome inhibitor bortezomib has been proposed as a novel therapeutic molecule for hepatocellular carcinoma (HCC), being able to reduce cell growth. Little information is available on the effect of bortezomib (BZB) on many of E2Fs, a family of transcription factors regulating normal and tumor cell proliferation. Our data show, for the first time, the BZB effect on expression of E2F family members in HCC cell lines is not limited to the most studied E2F1, but, it extends also to other E2F members, in particular E2F2, E2F8 and E2F6, and the effect is phenotypic dependent.
Publish Date 2014-02-19 16:57
Citation Baiz D, Dapas B, Farra R, Scaggiante B, Pozzato G, Zanconati F, Fiotti N, Consoloni L, Chiaretti S, Grassi G. Bortezomib effect on E2F and cyclin family members in human hepatocellular carcinoma cell lines. World J Gastroenterol 2014; 20(3): 795-803
URL http://www.wjgnet.com/1007-9327/full/v20/i3/795.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i3.795
Full Article (PDF) WJG-20-795.pdf
Full Article (Word) WJG-20-795.doc
Manuscript File 4403-Review.docx
Answering Reviewers 4403-Answering reviewers.pdf
Copyright License Agreement 4403-Copyright assignment.pdf
Peer-review Report 4403-Peer reviewer(s).pdf
Scientific Editor Work List 4403-Scientific editor work list.doc